OASM.Y Stock Overview
Develops, produces, markets, and sells drugs in the field of human and veterinary oncology in Sweden. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Vivesto AB Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | SEK 0.05 |
| 52 Week High | SEK 0.05 |
| 52 Week Low | SEK 0.02 |
| Beta | 0.54 |
| 11 Month Change | 0% |
| 3 Month Change | n/a |
| 1 Year Change | n/a |
| 33 Year Change | -92.99% |
| 5 Year Change | -96.73% |
| Change since IPO | -98.65% |
Recent News & Updates
Recent updates
Shareholder Returns
| OASM.Y | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 0% | -3.7% | 0.3% |
| 1Y | n/a | 15.2% | 31.1% |
Return vs Industry: Insufficient data to determine how OASM.Y performed against the US Biotechs industry.
Return vs Market: Insufficient data to determine how OASM.Y performed against the US Market.
Price Volatility
| OASM.Y volatility | |
|---|---|
| OASM.Y Average Weekly Movement | n/a |
| Biotechs Industry Average Movement | 9.8% |
| Market Average Movement | 6.2% |
| 10% most volatile stocks in US Market | 15.8% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: OASM.Y's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: Insufficient data to determine OASM.Y's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1988 | 4 | Erik Kinnman | www.vivesto.com |
Vivesto AB develops, produces, markets, and sells drugs in the field of human and veterinary oncology in Sweden. Its lead product is Apealea (paclitaxel micellar) for the treatment of ovarian cancer. The company’s products portfolio includes Docetaxel micellar, a patented formulation that combines cytotoxin docetaxel with XR-17, which is in Phase 1b clinical trial for the treatment of prostate cancer; and Cantrixil to treat ovarian cancer.
Vivesto AB Fundamentals Summary
| OASM.Y fundamental statistics | |
|---|---|
| Market cap | US$13.57m |
| Earnings (TTM) | -US$8.43m |
| Revenue (TTM) | US$601.41k |
22.6x
P/S Ratio-1.6x
P/E RatioIs OASM.Y overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| OASM.Y income statement (TTM) | |
|---|---|
| Revenue | SEK 6.67m |
| Cost of Revenue | SEK 0 |
| Gross Profit | SEK 6.67m |
| Other Expenses | SEK 100.10m |
| Earnings | -SEK 93.43m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
Feb 20, 2025
| Earnings per share (EPS) | -0.17 |
| Gross Margin | 100.00% |
| Net Profit Margin | -1,401.67% |
| Debt/Equity Ratio | 0% |
How did OASM.Y perform over the long term?
See historical performance and comparison